Monkey pox $$$$$$$ immunity
Thank you guys for selling on the news $))))))) weeeeeeee
Merry Christmas $$$$$$ 80.00 to 110.00
“The INSPIRE study achieved its primary objective of identifying patient populations that may benefit from IRX-2 in the neoadjuvant setting,” said Matt Angel, Ph.D., Brooklyn’s CEO. “These encouraging results are a testament to the design of the INSPIRE study and provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors. The potential to offer an effective, well tolerated treatment to patients with advanced head and neck cancer who are ineligible for chemotherapy is particularly exciting.”
Rock on my brother ‘ 100.00 stock $$$$$$$
Time to load… .58-.62 accumulation.
$BTX: There goes $13..... now we get ready to roll
Saw this dwelling but its definitely ready to ramp now.
Give us $20 first
$BTX: Maybe $30..... but I agree........
Stepping in for some here now with 5k shares at $12.50 :)
Good News on new mRNA shares facility yesterday with Factor BioScience.
Buy out coming
have you done an update on this? $BTX
BTX > "company said it has established a research and development center in Cambridge, Mass., to pursue its mRNA-based gene editing and cellular therapies.
The company said it has co-located with Factor Bioscience Limited and Novellus Therapeutics Limited, from which Brooklyn has acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on the patented technology and know-how of Factor and Novellus.
"We believe co-locating with Factor and Novellus will promote our capability to leverage our collaboration and further our objectives in developing a diversified portfolio of new, advanced therapeutics," said Howard J. Federoff, Brooklyn's chief executive and president.
Brooklyn's recently licensed platform from Factor and Novellus includes three novel technologies that the company expects to pursue at its new R&D location.
The first is a highly efficient mRNA cell reprogramming method. The second is a mRNA-based gene editing technology which can be applied to both allogeneic and autologous cells and which eliminates potential for off-target effects. The third is a proprietary tunable nanolipid delivery system that provides efficient non-viral vector-based delivery of mRNA ex vivo and in vivo to skin, brain, eye and lung tissue."
Write to Chris Wack at firstname.lastname@example.org
S-1 shelf placement may be completed today. $20.00+ on the horison.
Under $20.00 is a great entry. Any time a huge PR/news, catalysts will rocket BTX to all time highs!
Missed the entry on pullback to $13.00... will wait for better entry by EOM.
It is pretty clear that BTX has to provide more information to shareholders for the sellers to stop selling and finding new buyers.
About time for another Brooklyn run to 77.77
77.77 in AH > BOOOOOOOOOM! MONDAY MORNING!!!!!
RSI still is pretty high. Screaming buy when/if it hits RSI of 30.
No volume on that turd no thanks
Naw. It's shorting do a rinse & repeat. Squeeze 2.0 coming soon.
Looks like the crowd is exiting. To stop this bleeding, BTX really needs to come out with very positive corporate developments.
The harder the run, the more pain there is on the way down. But there will be a higher base that will be built somewhere. Just do not know where that base is.
Other biotechs have begun their consolidation already with that higher base.
Moved some of my profits here to CUBT.
Better to get in low and get out when it is high than the other way around. Reddit moves are great because they happen so fast. But once it cools off--well talk to anyone who bought GME at $400.
CUBT is in biotech too. And has an exclusive patent from the NIH. At $0.13 right now.
BTX could run again if the Reddit crowd keeps it up, but a $20 move is only a 30% gain. Looking for much more than that now.
Yeah so this was another REDDIT short squeeze play like GameStop (GME) and AMC. Wish I'd a known!!
Careful. Got out at the open--not because I do not think this cannot become another GME play, just that at some point ....
Is Brooklyn ImmunoTherapeutics the next GameStop?
May 01, 2021 4:00 PM ETBrooklyn ImmunoTherapeutics, Inc. (BTX)
By: Jonathan M Block, SA News Editor
One of the best performing stocks in April was Brooklyn ImmunoTherapuetics (NYSEMKT:BTX), which only began trading in late March.
Shares have risen more than 1200% in the last month.
Brooklyn was formed through a reverse merger with the trivia apps company NTN Buzztime.
In April, Brooklyn's biggest announcement was its acquisition of an exclusive license for mRNA gene editing and cell therapies technology.
However, given the sudden rise in share price on little news or other catalysts, some are saying that Brooklyn is the target of a short squeeze play.
Users on the Wall Street Bets Reddit channel, the same group behind GameStop's spectacular rise earlier this year, have said for some time they have wanted to target biotech stocks as potential short squeeze plays.
Joshua Rodriguez of CNA Finance noted last month that before it became Brooklyn Immunotherapeutics, NTN Buzztime was heavily shorted and after the merger, the public float was only 1.12M shares.
The company's sole asset, IRX-2, is in phase 2b for squamous cell cancer of the head and neck and results are expected by the end of 1H 2021.
I was alerted 10 days ago it was under $5 but didn't expect it to move. $$$$$$!
This is a 10 day bar/volume chart of hourly pricing for BTX. As one can observe there was a slight uptick in pricing 10 days ago. Hardly noticeable. Volume nothing to write home about. Later, as pricing and volume increased, the ticker symbol appeared on the Barchart Top 100 list. I use it as an alert. What happened after that is impressive. It is in situations like this when I increase my position size, because it makes sense to do so.
77.77 in AH > BOOOOOOOOOM! MONDAY MORNING!!!!!
Always tough to rebuy at higher prices. But it was worth it this time for me.